

Docket No.: 112958.120US

PATENT/OFFICIAL

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

#3

In re Application of

Harry HOLTHÖFER

Serial No. Not yet assigned

Group Art Unit: Not yet assigned

U.S. National Phase of International
Application Number PCT/F100/00540

Filed: December 14, 2001

Examiner: Not yet assigned

For: USE OF SOLUBLE PROTEIN MOLECULES EXPRESSED BY THE
PANCREAS AND KIDNEY GLOMERULUS

INFORMATION DISCLOSURE STATEMENT

Honorable Commissioner for Patents
Washington, D. C. 20231

Sir:

In accordance with the provisions of 37 C.F.R. §§ 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the documents listed on the attached form PTO-1449. It is respectfully requested that the documents be expressly considered during the prosecution of this application, and that the documents be made of record therein and appear among the "References Cited" on any patent to issue therefrom.


Copies of the documents listed on sheets 1 and 2 of Form PTO-1449, which were cited in the prosecution of the corresponding PCT patent application, are enclosed. Further submitted herewith for consideration by the Examiner is a copy of a nucleotide sequence comparison provided by the PCT Examining Authority which

includes the cited Kawachi et al. reference.

In accordance with 37 C.F.R. §§ 1.97(g) and (h), the filing of this IDS should not be construed as a representation that a search had been made or that information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56 (b), or that any cited document listed or attached is, or constitutes, prior art. Unless otherwise indicated, the date of publication indicated for an item is taken from the face of the item, and Applicant reserves the right to prove that the date of publication is in fact different.

Applicants believe no fee is due at this time as this Statement is being filed with the above-referenced application. However, the Commissioner is authorized to charge any deficiency in any fees pursuant to 37 CFR § 1.17 associated with this communication and to credit any excess payment to Deposit Account No. 08-0219.

Respectfully submitted,



Jason J. Schwartz
Registration No. 43,910

HALE AND DORR LLP
1455 Pennsylvania Avenue, NW
Washington, DC 20004
TEL 202.942.8490
FAX 202.942.8484
Date: December 14, 2001

10/018094
JO Sec'd PCT/PTO 1.4 DEC 2001
PTO/SB/08A1 (08-08)
Approved for release through 10/31/2002. OMB 0651-0031
Mark O'Connor, U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449A/PTO

(use as many sheets as necessary)

Sheet | 1

of 2

Application Number

Filing Date

December 14, 2001

First Named Inventor

Harry HOLTTHOFER

Group Art Unit

Examiner Name

Attorney Docket Number

112958.120US1

[illegible][illegible]

Examiner
Signature

Date
Considered

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:** Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>		Complete if Known	
		Application Number	
		Filing Date	December 14, 2001
		First Named Inventor	Harry HOLTHOFER
		Group Art Unit	
		Examiner Name	
Sheet 2	of 2	Attorney Docket Number	112958.120US1

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		KESTILA, Marjo et al (1998) "Positionally Cloned Gene for a Novel Glomerular Protein--Nephrin--Is Mutated in Congenital Nephrotic Syndrome," Mol. Cell 1:575-582.	
		AHOLA, Heikki et al. (1999) "Cloning and Expression of the Rat Nephrin Homolog," American Journal of Pathology 155(3): 907-913.	
		TOPHAM, Peter S. et al. (1999) "Nephritogenic mAb 5-1-6 Is directed at the extracellular domain of rat nephrin," The Journal of Clinical Investigation 104(11):1559-1566.	
		HOLZMAN, Lawrence B. et al. (1999) "Nephrin localizes to the slit pore of the glomerular epithelial cell" Kidney International 56:1481-1491.	
		Kawachi H. et al. "Cloning of rat nephrin and its expression and localization in proteinuric states" EMBL/GenBank/DBJ databases, Emrod accession no. Af161715, Dec. 12, 1999.	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.